ENGINEERING THE NEXT CHAPTER IN BIOTECH.
A biotech startup spun out from Newcastle University in 2019, 3D Bio-Tissues (3DBT) is at the forefront of producing bio-equivalent tissues for clinical and cellular agriculture, applying novel bio-inspired manufacturing processes to generate complex structures.
POWERED BY BSF ENTERPRISE
3DBT is a wholly-owned subsidiary of BSF Enterprise PLC—a listed (LON: BSFA) biotech investor focused on the development of the next generation of cutting-edge biotech solutions. BSF Enterprise aims to radically transform the delivery of sustainable solutions across a variety of sectors including tissue engineering.
3DBT's technology is built upon 20 years of basic research. Applying the hypothesis that a better understanding of biology will lead to improved approaches to tissue engineering we have developed a powerful new process called tissue templating.
Tissue templating is an in-house engineering platform that takes a bio-inspired, bottom-up approach to tissue engineering to create structured, functional, and scalable tissues.
Structured - A Tissue-Templating approach to engineering tissues is cell-based which results in highly organised structures accurate at a nano- and macro-scale.
Functional - Engineered tissue with appropriate hierarchical ECM arrangement produces unrivalled performance and functionality.
Scalable - Production suits a traditional centralised manufacturing approach, in which hundreds of tissue-engineered products can be produced daily and without the use of animal components.
TECHNOLOGY BUILT UPON SCIENCE.
Assessment of Corneal Substrate Biomechanics and its Effect on Epithelial Stem Cell Maintenance and Differentiation.
4D Corneal Tissue Engineering: Achieving Time‐Dependent Tissue Self‐Curvature through Localized Control of Cell Actuators.
Template Curvature Influences Cell Alignment to Create Improved Human Corneal Tissue Equivalents.